于福全

[摘要]目的 探讨苯磺酸左旋氨氯地平联合缬沙坦治疗原发性高血压的临床效果。方法 选取2014年1月～2016年1月我院收治的100例原发性高血压患者作为研究对象，采取随机数字表法将其分为观察组和对照组，每组各50例。对照组患者予缬沙坦80 mg治疗，每天1次晨服，观察组患者予苯磺酸左旋氨氯地平2.5mg联合缬沙坦80 mg治疗，每天1次晨服，连用8周。对比分析两组患者的临床疗效、治疗前后的SBP、DBP水平及生活质量各项评分。结果 观察组患者治疗后的临床总有效率（96.00%）高于对照组（78.00%），差异有统计学意义（P<0.05）。观察组患者治疗后的SBP水平[（112.8±15.2）mmHg]、DBP水平[（72.8±17.2）mmHg]均显著低于对照组[（118.5±13.8）、（85.3±15.3）mmHg]，差异有统计学意义（P<0.05）。观察组患者治疗后的生活质量各项评分分别显著高于对照组，差异有统计学意义（P<0.05）。结论 苯磺酸左旋氨氯地平联合缬沙坦治疗原发性高血压临床疗效确切，可以显著減轻患者的临床症状，提高患者的生活质量。

[关键词]原发性高血压；苯磺酸左旋氨氯地平；缬沙坦；生活质量

[中图分类号] R544.1 [文献标识码] A [文章编号] 1674-4721（2017）11（a）-0026-04

Clinical observation of Levamlodipine Besylate combined with Valsartan in the treatment of essential hypertension

YU Fu-quan

Department of the Second Vasculocardiology，Pulandian District Central Hospital in Dalian City，Liaoning Province，Dalian 116200，China

[Abstract]Objective To study the clinical efficacy of Levamlodipine Besylate combined with Valsartan in the treatment of essential hypertension.Methods 100 patients with essential hypertension who were admitted to our hospital from January 2014 to January 2016 were selected as the study subjects.According to the random number table method，the patients were divided into observation group and control group，with 50 cases in each group.The control group was given Valsartan of 80 mg，administered in the morning once a day.The observation group was given Levamlodipine Besylate of 2.5 mg and Valsartan of 80 mg，administered in the morning once a day.The patients were administered for 8 weeks continuously.The clinical efficacy，SBP and DBP levels before and after the treatment and quality of life scores were compared and analyzed between the two groups.Results The total clinical effective rate was 96.00% after treatment in the observation group，which was higher than that in the control group （78.00%），the difference was statistically significant （P<0.05）.The levels of SBP [（112.8±15.2） mmHg] and DBP [（72.8±17.2） mmHg] in the observation group after the treatment were significantly lower than those in the control group[（118.5±13.8），（85.3±15.3） mmHg]，the differences were statistically significant （P<0.05）.The scores of life quality after the treatment in the observation group were significantly higher than those in the control group，the differences were statistically significant （P<0.05）.Conclusion The clinical efficacy of levamlodipine besylate combined with valsartan in the treatment of essential hypertension is significant，which can significantly reduce the clinical symptoms and improve the quality of life of patients.endprint

[Key words]Essential hypertension；Levamlodipine Besylate；Valsartan；Quality of life

研究证实，高血压是许多心脑血管疾病发病的重要危险因素，致残致死率高，严重影响患者的身体健康与生命安全[1]。因此，安全有效地控制血压，降低其对心、脑、肾等靶器官的损害，提高患者的生活质量，降低病死率和致残率是高血压治疗的目标[2]。血管紧张素受体拮抗剂（ARB）或钙离子拮抗剂（CCB）是临床常用的降压药物之一，但单一用药效果并不明显，若增加药物剂量，易加重不良反应。有研究发现，单药治疗高血压患者的血压控制率仅40%，联合治疗控制率升到60%～80%[3]。目前临床多主张联合用药，苯磺酸左旋氨氯地平属于第三代钙离子拮抗剂类抗高血压药物之一[4]，缬沙坦是非完全特异性血管紧张素Ⅱ受体拮抗剂[5]，本研究选取我院收治的100例原发性高血压患者作为研究对象，通过观察苯磺酸左旋氨氯地平联合缬沙坦治疗原发性高血压的临床疗效，探讨原发性高血压临床治疗方法的选择，现报道如下。……